Decoquinate
Based on 1 Customer Validation
Decoquinate is an orally active, selective inhibitor of the mitochondrial bc1 complex, targeting Eimeria spp. sporozoites and first generation schizonts, and Plasmodium spp. Decoquinate inhibits electron transfer by competitively binding to the mitochondrial cytochrome b system, blocking the parasite's energy metabolism, thereby inhibiting its development and reproduction. Decoquinate has significant anticoccidial activity, preventing intestinal damage and improving host growth performance, and also has inhibitory effects on the liver and blood stages of Plasmodium. Decoquinate is mainly used in veterinary research to prevent and treat coccidiosis in ruminants and poultry.
For research use only. We do not sell to patients.
- Purity: 98.80%
- CAS No.: 18507-89-6
- Formula: C24H35NO5
- Molecular Weight:417.54
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
All Parasite Isoforms
More
Biological Activity
|
Plasmodium |
Coccidia |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
0.0008 ppm
Compound: Decoquinate
|
Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the absence of inhibitor; value given as 0.004-0.0008
Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the absence of inhibitor; value given as 0.004-0.0008
|
[PMID: 9873375] |
| Hepatocyte | IC50 |
0.0008 ppm
Compound: Decoquinate
|
Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of iproniazid; value given as 0.004-0.0008
Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of iproniazid; value given as 0.004-0.0008
|
[PMID: 9873375] |
| Hepatocyte | IC50 |
0.0008 ppm
Compound: Decoquinate
|
Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of Tranylcypromine; value given as 0.004-0.0008
Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of Tranylcypromine; value given as 0.004-0.0008
|
[PMID: 9873375] |
| HepG2 | IC50 |
>100 μM
Compound: 92307901
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
0.0054 μM
Compound: 92307901
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| WI-38 | IC50 |
>100 μM
Compound: 1; DQ
|
Cytotoxicity against human WI38 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human WI38 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27210430] |
1. In vitro antimalarial experiment: Decoquinate (nanoformulation; 48-72 h) significantly inhibited the growth of Plasmodium falciparum in the liver and blood stages in vitro, with an IC50 of 2.18 ng/mL for the liver stage and 0.05 ng/ml for the blood stage.[2] 2. Derivative activity experiment: Decoquinate derivatives had a strong inhibitory effect on Chloroquine (HY-17589A) sensitive strain NF54 and resistant strains K1 and W2, with an activity 5 times that of Decoquinate, and low toxicity to human fibroblasts.[3]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Decoquinate (0.5-1 mg/kg; administered in feed; once daily; for at least 28 days) effectively inhibits and prevents coccidiosis in the coccidiosis model of ruminants (calves, lambs, goats), reduces intestinal damage and oocyst excretion, and improves host growth performance. Decoquinate effectively treats and prevents coccidiosis, reduces intestinal damage and oocyst excretion, and improves host growth performance[1].
2. Toxoplasma prevention experiment:
Decoquinate (2 mg/kg; administered in feed; once daily; for 14 weeks) can prevent abortion and perinatal loss caused by Toxoplasma infection in pregnant sheep Toxoplasma infection model, delay febrile reaction and reduce placental damage[1].
3. Antimalarial experiment of nanoformulation:
Decoquinate nanoformulation (1.25 mg/kg; oral; once a day; 3 days) significantly inhibits the growth of liver-stage Plasmodium in a mouse Plasmodium infection model, with an efficacy 15 times that of microparticle formulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 18507-89-6
-
Appearance Solid
-
Molecular Weight 417.54
-
Formula C24H35NO5
-
Color White to off-white
-
SMILES
O=C(C1=C(O)C2=CC(OCCCCCCCCCC)=C(OCC)C=C2N=C1)OCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
H2O : < 0.1 mg/mL (insoluble)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Taylor MA, et, al. The history of decoquinate in the control of coccidial infections in ruminants. J Vet Pharmacol Ther. 2012 Oct;35(5):417-27. [Content Brief]
[2]. Wang H, et al. Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice. Nanomedicine. 2014 Jan;10(1):57-65. [Content Brief]
[3]. Beteck RM, et al. Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. Bioorg Med Chem Lett. 2016 Jul 1;26(13):3006-3009. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)